Financial Data and Key Metrics Changes - Q4 2025 revenue totaled $469 million, with Adjusted EBITDA at $37.8 million, exceeding the midpoint of guidance [25] - For fiscal year 2025, baseline revenue was $1.7 billion, and Adjusted EBITDA would have been approximately $141 million [25] - The Medical Expense Ratio (MER) for 2025 was 89%, with Q4 MER at 95%, driven by out-of-period true-ups [26][19] - The company expects 2026 revenue to reach $2.5 billion at the midpoint, representing a growth of approximately 30% [10] Business Line Data and Key Metrics Changes - Oncology is projected to contribute approximately 65% of company revenue in 2026, up from 36% in 2025 [5] - The 2026 Performance Suite launches are expected to generate approximately $900 million in revenue, representing 37% of total 2026 revenue [11] - The company anticipates a MER of approximately 93% for 2026, compared to 89% in 2025 [34] Market Data and Key Metrics Changes - The managed care industry is undergoing a multi-year margin recovery cycle, leading health plans to seek solutions to lower costs while improving quality [21] - The company is experiencing a contraction in exchange membership, which presents near-term headwinds [21] Company Strategy and Development Direction - The company aims to capture market share through new partnerships and is focused on disciplined capital allocation [4] - Evolent is transitioning contracts to the Enhanced Performance Suite model, which includes revenue rate adjustments and downside protections [8] - The company is leveraging technology and AI to improve operational efficiency and reduce costs [23] Management's Comments on Operating Environment and Future Outlook - Management is confident in the growth trajectory for 2026, despite near-term challenges from exchange membership declines [16] - The company believes it is well-positioned to deliver earnings growth as new contracts mature and operational initiatives take effect [36] - Management emphasizes a conservative approach to reserving for new contracts, which is expected to create temporary headwinds in 2026 [46] Other Important Information - The company ended 2025 with net debt of $782 million, below the expected range, and has no maturities until late 2029 [20] - A significant non-cash goodwill impairment was recorded due to market valuation declines, which does not impact EBITDA or cash flow [27] Q&A Session Summary Question: Can you help us understand the rationale behind the conservative approach to reserving? - Management explained that new contracts require different levels of reserves, leading to a more conservative approach initially due to new data flow and implementation challenges [46][47] Question: What are the early indicators for new membership this year? - Management noted that early indicators are consistent with a 40% reduction in exchange membership, primarily due to clients proactively stepping away from risk pools [50][51] Question: How should we model stock-based compensation and capital deployment for 2026? - Management indicated that stock-based compensation will remain consistent with past levels and emphasized a focus on deleveraging while being open to liability management opportunities [54][56] Question: Can you clarify the expected oncology cost trends for 2026? - Management stated that oncology trends are expected to remain stable, similar to 2025, with various mechanisms in contracts to adjust for changes in acuity [60][61] Question: What are the swing factors in the EBITDA guidance? - Management highlighted that MER is a significant factor, along with the potential for accelerated savings from clinical programs [80]

Financial Data and Key Metrics Changes - Q4 2025 revenue totaled $469 million, with Adjusted EBITDA at $37.8 million, exceeding the midpoint of guidance [24] - For fiscal year 2025, baseline revenue was $1.7 billion, and Adjusted EBITDA would have been approximately $141 million after adjusting for the ACO divestiture [24] - The Medical Expense Ratio (MER) for 2025 was 89%, improving by nearly 700 basis points compared to 2024 [18][24] - The company forecasts 2026 revenue at $2.5 billion, representing approximately 30% growth, with Adjusted EBITDA guidance at $125 million [9][30] Business Line Data and Key Metrics Changes - Oncology is expected to contribute approximately 65% of total revenue in 2026, up from 36% in 2025, indicating a significant focus on this area for growth [4] - The MER for the fourth quarter was 95%, driven by out-of-period true-ups, but underlying medical trends remained stable [24][25] - The company anticipates that the existing Performance Suite business will contribute $35 million of additional profitability despite revenue declines from exchange-related membership contraction [30] Market Data and Key Metrics Changes - The managed care industry is experiencing a multi-year margin recovery cycle, leading health plans to seek solutions that lower costs while improving quality [20] - The company is facing near-term headwinds due to contracting membership in the industry, which is expected to impact revenue [20] - The Specialty TNS business is projected to deliver modest underlying growth in 2026, despite significant headwinds from exchange membership declines [30] Company Strategy and Development Direction - The company aims to capture market share through new partnerships while maintaining a disciplined approach to underwriting [20] - Evolent is focusing on enhancing operational efficiency through technology and AI, with a goal to automate 80% of baseline authorization volume [21] - The company is committed to prioritizing debt paydown as its primary capital allocation focus while investing in product and technology for long-term growth [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate near-term challenges and capitalize on substantial opportunities in the market [42] - The outlook for 2026 includes expectations for strong Performance Suite growth, with revenue reaching an all-time high, despite temporary headwinds from reserving methodologies [28] - Management noted that the demand for Evolent's services has never been greater, with a clear strategy to expand customer footprint under strong terms [20] Other Important Information - The company ended 2025 with net debt of $782 million, below the expected range, and has no maturities until late 2029 [19] - A large non-cash goodwill impairment was recorded due to market valuation declines, which does not impact EBITDA or cash flow [26] Q&A Session Summary Question: Can you help us understand the rationale behind the conservative approach to reserving? - Management explained that new contracts require different levels of reserves, leading to a more conservative approach initially due to new data flow and implementation [44][45] Question: What are the early indicators for new membership behavior this year? - Management indicated that early indicators are consistent with a 40% reduction in exchange membership, primarily due to clients proactively stepping away from risk pools [48][49] Question: How should we model stock-based compensation and capital deployment for 2026? - Management advised that stock-based compensation should remain consistent with past assumptions and emphasized a focus on deleveraging while being open to liability management opportunities [52][55] Question: Can you clarify the expected oncology cost trends for 2026? - Management stated that oncology trends are expected to remain stable, with no significant changes anticipated compared to 2025 [58][60] Question: What are the swing factors affecting the high and low ends of the EBITDA guidance? - Management highlighted that the Medical Expense Ratio (MER) is a significant factor, along with the potential for accelerated savings from clinical programs [77][78]